Karolinska Institutet
Browse

Nuclear medicine imaging of lung cancer and esophagus cancer

thesis
posted on 2024-09-03, 05:51 authored by Gunnar Herlin

Background: Somatostatin receptors (SSTRs) occur in cancer tissue, and 99mTc-depreotide is a labelled somatostatin receptor analogue, binding to SSTRs subtype 2, 3, and 5.

Purpose: The general aim of the present thesis was to study somatostatin receptor scintigraphy (SSTRS) with 99mTc-depreotide in the diagnosis and characterization of cancers in the lung and oesophagus.

Study I evaluated the diagnostic value of the SSTRS with 99mTc-depreotide in 99 patients with suspected lung cancer. The sensitivity to detect malignancy was 94%, and to detect lung cancer 98%. The specificity was calculated on two sets of data. When all cases are used, the specificity was 52%. If the 12 pneumonias are excluded, the specificity was 77%.

Study II was performed on 19 patients with histologically proven non-small-cell lung cancer (NSCLC), where the expression of SSTR subtype 2 was looked for and found by immunochemical methods. The quantitative evaluation of 99mTc-depreotide was performed using region-of-interest analysis and includes tumour counts/cm3, background counts/cm3, and the ratio between tumour and background counts. SSTR subtype 2 expression was positively correlated to the degree of the tumour’s differentiation (p < 0.05). 99mTc-depreotide uptake in tumour cells did not correlate with tumour grade or SSTR subtype 2, MIB-1, or p53 expression.

Study III showed the feasibility of imaging oesophageal carcinoma with SSTRS with 99mTc- depreotide and optimal time intervals for imaging. None of the 13 cancer-free Barrett’s oesophagus patients in this study showed an increased 99mTc-depreotide uptake.

Study IV investigated the expression of SSTRs of subtype 2A, 2B, 3, and 5 in 28 patients with suspected oesophageal cancer, where expression was detected in small amount in adenocarcinoma and was absent in squamous cell carcinoma. There was no correlation between the 99mTc-depreotide uptake and the amount of SSTRs, and no correlation between the amount of SSTRs and the differentiation grade of the tumour.

Conclusion: SSTRS with the labeled somatostatin receptor analogue 99mTc-depreotide has a very high sensitivity for detecting lung cancer. A negative scintigraphy strongly suggests a benign lesion, and the method is useful in decision making with respect to surgery. There is an expression of SSTRS subtype 2 in NSCLC with a positive correlation between tumour differentiation and presence of SSTR subtype 2. There is no correlation between 99mTc-depreotide uptake compared to tumour differentiation, presence of SSTR subtype 2, p53, or MIB-1, and SSTRS cannot be used as a prognostic factor in patients with lung cancer.

SSTRS with 99mTc-depreotide of oesophageal cancer is feasible, but not suitable, for either screening or primary diagnosis, because of the method’s modest sensitivity. However, this method has a high specificity. The majority of patients with adenocancer of the oesophagus have a low amount of SSTRs, while most of the patients with squamous cell cancer do not have any of SSTRs.

List of scientific papers

I. Role of scintigraphy with Technetium-99m depreotide in diagnosis and management of patients with suspected lung cancer. Axelsson R, Herlin G, Bååth M, Aspelin P, Kölbeck K-G. Acta Radiol. 2008;49:295-302.
https://doi.org/10.1080/02841850701793777

II. Quantitative assessment of 99mTc-depreotide uptake in patients with non-small-cell lung cancer: immunihistochemical correlations. Herlin G, Kölbeck K-G, Menzel PL, Svensson L, Aspelin P, Capitano A, Axelsson R. Acta Radiol. 2009;50:902-8.
https://doi.org/10.1080/02841850903127477

III. Feasibility of imaging esophageal cancer with labeled somatostatin analogue. Herlin G, Ideström L, Lundell L, Aspelin P, Axelsson R. Int J Mol Imaging. 2011:279345.
https://doi.org/10.1155/2011/279345

IV. Quantitative assesment of 99mTc-depreotide uptake in esophageal cancer and precursor conditions and its reflection in immunohistochemically detected somatostatin receptors. Herlin G, Lundell L, Öst Å, Aspelin P, Svensson L, Axelsson R. [Manuscript]

History

Defence date

2011-09-23

Department

  • Department of Clinical Science, Intervention and Technology

Publisher/Institution

Karolinska Institutet

Main supervisor

Axelsson, Rimma

Publication year

2011

Thesis type

  • Doctoral thesis

ISBN

978-91-7457-403-6

Number of supporting papers

4

Language

  • eng

Original publication date

2011-08-24

Author name in thesis

Herlin, Gunnar

Original department name

Department of Clinical Science, Intervention and Technology

Place of publication

Stockholm

Usage metrics

    Theses

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC